AGO2 and pancreatic neoplasm: To investigate whether PVT1 can act as a ceRNA in pancreatic cancer gemcitabine chemoresistance, we performed bioinformatic analysis, luciferase assays and RNA immunoprecipitation assays with the Ago2 protein, which revealed PVT1 to engage in complementary binding with miR-619-5p, which is related to cisplatin resistance [40].